演題抄録

International Session

開催概要
開催回
第54回・2016年・横浜
 

本邦における悪性黒色腫の治療:近年のupdate

演題番号 : IS17-3

[筆頭演者]
中村 泰大:1 

1:埼玉医科大学・国際医療センタ-・皮膚腫瘍科・皮膚科

 

The recent development of immune checkpoint inhibitors, which enhance anti-tumor immunity by blocking negative regulators of immunity, and molecular targeted agents, which inhibit the oncogenes that drive the aberrant tumor growth, have dramatically improved the tumor response and prognosis in patients with advanced melanoma. However, there seems to be several differences between Japan and the USA in the treatment situation for patients with melanoma.
In Japan, the PD-1 antibody nivolumab was approved in June 2014, its first approval worldwide, followed by the approval of vemurafenib in December 2014 and ipilimumab in June 2015. Recently, in March 2016, combination therapy targeting BRAF + MEK by using dabrafenib and trametinib was approved. Pembrolizumab, which was the first approved PD-1 antibody in the USA, and combination immunotherapy using ipilimumab and nivolumab have not been approved in Japan.
The incidence of each clinical type of melanoma shows huge differences between ethnic Japanese and Caucasian individuals. For example, there are fewer patients with melanoma harboring BRAF mutations in Japan than in the USA. In addition to the different sequence of approval of new drugs between two countries, differences in racial characteristics between Japanese and Caucasian individuals also influence the treatment selection for advanced melanoma in Japan.
Although there have been few advances in surgical treatment and adjuvant therapy for melanoma, in Japan, we have several clinical trials that will be initiated or are ongoing regarding surgery for subungual melanoma and adjuvant therapy with interferon beta (JCOG 1602 and JCOG1309).
The goals of this presentation are to describe the latest updates on the treatment for advanced melanoma worldwide and to review the treatment of patients with melanoma and the characteristics of our clinical practice in Japan over the last year.

前へ戻る